002030 達安基因
按盤價 
6.640 +0.600 (+9.934%)
6.640 +0.600 (+9.934%) | 2026/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 149,439 | -11.65% | 757,662 | 853,024 | 1,180,897 | 12,046,135 | |
| 減：營業總成本 | 205,156 | -13.86% | 1,054,915 | 1,058,065 | 1,133,441 | 5,191,468 | |
| 其中:營業成本 | 103,461 | -11.30% | 512,169 | 532,743 | 584,929 | 3,271,535 | |
| 財務費用 | (2,713) | -73.62% | (36,173) | (65,069) | (74,749) | (111,036) | |
| 資產減值損失 | (1,211) | -65.32% | (436,992) | (75,040) | (262,754) | (681,999) | |
| 公允價值變動收益 | (60,350) | -130.07% | 4,572 | (175,746) | 435,691 | 82,321 | |
| 投資收益 | (6,789) | -72.57% | 49,429 | (253,838) | (26,247) | 271,184 | |
| 其中：對聯營企業和合營企業的投資收益 | (10,832) | -58.55% | 6,212 | (271,331) | (46,101) | 129,360 | |
| 營業利潤 | (99,293) | -206.56% | (753,354) | (1,067,605) | 121,622 | 6,329,254 | |
| 利潤總額 | (99,845) | -206.41% | (756,988) | (1,071,163) | 113,536 | 6,318,937 | |
| 減：所得稅費用 | (1,649) | -103.87% | 23,533 | (132,051) | 41,804 | 891,378 | |
| 淨利潤 | (98,196) | -291.55% | (780,522) | (939,113) | 71,732 | 5,427,558 | |
| 減：非控股權益 | (41) | -97.51% | (36,143) | (13,943) | (32,928) | 15,217 | |
| 股東淨利潤 | (98,155) | -285.46% | (744,379) | (925,170) | 104,660 | 5,412,341 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.070 | -275.00% | -0.530 | -0.660 | 0.070 | 3.857 | |
| 每股派息 (元) * | -- | -- | -- | -- | 0.015 | 1.750 | |
| 每股淨資產 (元) * | 5.016 | -11.26% | 5.086 | 5.615 | 6.327 | 8.052 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 18/05/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
